Immunosuppressants for the prophylaxis of corneal graft rejection after penetrating keratoplasty

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2009, Pages

  Wei, Xin ^a   Chen, Zhiyu ^a   Wu, Taixiang ^a   Yinping, Deng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RAPAMYCIN; TACROLIMUS;

CLINICAL TRIAL; CORNEA TRANSPLANTATION; DRUG COST; DRUG EFFICACY; GRAFT REJECTION; GRAFT SURVIVAL; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAOCULAR HYPERTENSION; KERATITIS; LENGTH OF STAY; PENETRATING KERATOPLASTY; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; VISUAL ACUITY;

EID: 70249146483     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007603     Document Type: Review

References (43)

1. Algros MP, Angonin R, Delbosc B, Cahn JY, Kantelip B. Danger of systemic cyclosporine for corneal graft. Cornea 2002;21(6):613-614 (Pubitemid 34803670)
2. Arentsen JJ. Corneal transplant allograft reaction: possible predisposing factors. Transactions of the American Ophthalmological Society 1983;81:361-402.
3. Belin MW, Bouchard CS, Phillips TM.Update on topical cyclosporin A. Background, immunology, and pharmacology. Cornea 1990;9(3): 184-195
4. Chandler JW, Kaufman HE. Graft reactions after keratoplasty for keratoconus. American Journal of Ophthalmology 1974;77(4):543-547
5. Cosar CB, Laibson PR, Cohen EJ, Rapuano CJ. Topical cyclosporine in pediatric keratoplasty. Eye Contact Lens 2003;29(2):103-107
6. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook. org.
7. Dobbins KR, Price FW Jr, Whitson WE. Trends in the indications for penetrating keratoplasty in the midwestern United States. Cornea 2000;19(6):813-816
8. Statistical Report 2000. Eye Bank Association of America.
9. Eye Banking Statistical Report. Eye Bank Association of America.
10. Efficace F, Bottomley A, Osoba D, Gotay C, Flechtner H, D'haese S, et al.Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials - does HRQOL evaluation in prostate cancer research inform clinical decision making?. Journal of Clinical Oncology 2003;21(18):3502-3511 (Pubitemid 46594084)
11. Efficace F, Horneber M, Lejeune S, Van Dam F, Leering S, Rottmann M, et al.Methodological quality of patient-reported outcome research was low in complementary and alternative medicine in oncology. Journal of Clinical Epidemiology 2006;59(12):1257-1265 (Pubitemid 44711985)
12. Efficace F, Osoba D, Gotay C, Sprangers M, Coens C, Bottomley A. Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making. Annals of Oncology 2007;18(4):775-781 (Pubitemid 46523284)
13. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple,graphical test. BMJ 1997;315(7109): 629-634 (Pubitemid 27387172)
14. Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-136
15. Guerra G, Srinivas TR, Meier-Kriesche HU. Calcineurin inhibitor-free immunosuppression in kidney transplantation. Transplant International 2007;20(10):813-827 (Pubitemid 47390195)
16. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
17. Hill JC. The use of cyclosporine in high-risk keratoplasty. American Journal of Ophthalmology 1989;107(5):506-510
18. Hill JC, Maske R, Watson P.Corticosteroids in corneal graft rejection. Oral versus single pulse therapy. Ophthalmology 1991;98(3):329-333
19. Hill JC. Systemic cyclosporine in high-risk keratoplasty. Short-versus long-term therapy. Ophthalmology 1994;101(1):128-133 (Pubitemid 24044153)
20. Hughes WF. The treatment of corneal dystrophies by keratoplasty. American Journal of Ophthalmology 1960;50(6):1100-1114
21. Ing JJ, Ing HH, Nelson LR, Hodge DO, Bourne WM. Ten-year postoperative results of penetrating keratoplasty. Ophthalmology 1998; 105(10):1855-1865 (Pubitemid 28509725)
22. Inoue K, Amano S, Kimura C, Sato T, Fujita N. Long-term effects of topical cyclosporine A treatment after penetrating keratoplasty. Japanese Journal of Ophthalmology 2000;44(3):302-305 (Pubitemid 30417522)
23. Juni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42-46
24. Land W, Vincenti F. Toxicity-sparing protocols usingmycophenolate mofetil in renal transplantation. Transplantation 2005;80(2 Suppl): S221-34. (Pubitemid 41552909)
25. Liu E, Slomovic AR. Indications for penetrating keratoplasty in Canada, 1986-1995. Cornea 1997;16(4):414-419
26. Niederkorn JY.Mechanisms of Immune Privilege in the Eye and Hair Follicle. Journal of Investigative Dermatology Symposium Proceedings 2003;8(2):168-172
27. Price MO, Price FW. Efficacy of topical cyclosporine 0.05% for prevention of cornea transplant rejection episodes. Ophthalmology 2006; 113(10):1785-1790
28. Ramsay AS, Lee WR, Mohammed A. Changing indications for penetrating keratoplasty in the west of Scotland from 1970 to 1995. Eye 1997;11(3):357-360
29. Randleman JB, Stulting RD. Prevention and treatment of corneal graft rejection: current practice patterns (2004). Cornea 2006;25 (3):286-290
30. Reinhard T, Mayweg S, Sokolovska Y. Systemic mycophenolate mofetil avoids immune reactions in penetrating high-risk keratoplasty: preliminary results of an ongoing prospectively randomized multicentre study. Transplant International 2005;18(6):703-708 (Pubitemid 41726836)
31. Reis A, Reinhard T, Sundmacher R, Braunstein S, Godehardt E. Mycophenolate mofetil and FK506: two novel immunosuppressants inmurine corneal transplantation. Transplantation Proceedings 1998; 30(8):4344-4347 (Pubitemid 29013243)
32. Reis A, Reinhard T, Sundmacher R, Braunstein S, Godehardt E. comparative investigation of FK506 and cyclosporin A in murine corneal transplantation. Graefes Archive for Clinical & Experimental Ophthalmology 1998;236(10):785-789 (Pubitemid 28458680)
33. Reis A, Reinhard T, Voiculescu A.Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomised clinical trial. British Journal of Ophthalmology 1999;83(11): 1268-1271 (Pubitemid 29511811)
34. Shepherd WF, Coster DJ, Fook TC, Rice NS, Jones BR. Effect of cyclosporin A on the survival of corneal grafts in rabbits. British Journal of Ophthalmology 1980;64(3):148-153 (Pubitemid 10082838)
35. Siconolfi L. Mycophenolatemofetil (CellCept): immunosuppression on the cutting edge. AACN Clinical Issues 1996;7(3):390-402.
36. Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts. Ophthalmology 2001; 108(10):1838-1844
37. Sterne JAC, Egger M, Moher D(editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
38. Tabbara KF. Pharmacologic strategies in the prevention and treatment of corneal transplant rejection. International Ophthalmology 2007;28(3):223-232
39. Thompson RW, Price MO, Bowers PJ, Price FW. Long-term graft survival after penetrating keratoplasty. Long-term graft survival after penetrating keratoplasty. Ophthalmology 2003;110(7):1396-1402
40. Williams KA, Esterman AJ, Bartlett C, Holland H, Hornsby NB, Coster DJ.How effective is penetrating corneal transplantation? Factors influencing long-term outcome in multivariate analysis. Transplantation 2006;81(6):896-901. (Pubitemid 44641510)
41. Taixiang W, Guanjian L. What about the concepts, design, practice and report of allocation concealment and blinding exactly?. Chinese Journal of Evidence-Based Medicine 2007;7(3):203-207
42. Xi XH, Qin B, Jiang DY. [Cyclosporin A combined with dexamethasone in preventing and treating immune rejection after penetrating keratoplasty]. Hunan Yi Ke Da Xue Xue Bao. 2003;28(6):627-630
43. Yamagami S, Hamrah P, Zhang Q, Liu Y, Huq S, Dana MR. Early ocular chemokine gene expression and leukocyte infiltration after high-risk corneal transplantation. Molecular Vision 2005;11:632. * Indicates the major publication for the study (Pubitemid 41410211)